Clinical Trial Update: Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of bevacizumab, erlotinib, and imatinib in advanced clear cell renal cell carcinoma has completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Gleevec (Imatinib)
• Tarceva (erlotinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Clear Cell Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-01-14